NANOCOCHLEATES: A NOVEL CARRIER FOR DRUG DELIVERY

Mrunalini Unecha[1], Ajay Sabale[2], Prof. Santosh Waghmare[3], Dr. Hemant Kamble[4]

[1]Student, Department of Pharmaceutics, [2]Student, Department of Pharmacology, [3]Professor, Department of Pharmacy, [4]Principle, Department of Pharmacy,
[1,2,3,4]Loknete Shri Dadapatil Pharate College of Pharmacy, Mandavgan Pharate, Shirur, Pune, Maharashtra.

Abstract: Nanocochleates are novel drug delivery system based on the science of entraping drug molecule into the diverse construction containing multilayered lipid bilayer rolled up in cigar like spiral structure. The nanocochleate structure gives security to epitomized atom structure encompassing brutal climate. Likewise it can possibly convey both the hydrophilic and lipophilic medication atom as it contains both the structures on its surface and its construction. Nanocochleates can be ready by numerous techniques and can be utilized to convey numerous dynamic specialists for some applications. Nanocochleates is having extremely less constraints than that of other measurements structures and framework and consequently, it turns out to be generally pertinent and more potential drug delivery system.

Introduction:

Different formulations with liposomes permitted the development of another class of the drug vehicles called "COCHLEATE." Cochleates are strong particulates which are comprised of enormous ceaseless, lipid bi-layer sheets moved up in a twisting design with no internal aqueous phase between them. This innovation had the option to answer the difficulties of oral conveyance of various sort of natural atoms, particularly the hydrophobic ones. Cochleates vary from liposomes in having without water inside, bar molded, and unbending stable construction is displayed in Figure 1.[1]

The nanocochleate drug delivery vehicle depends on encapsulating drugs in complex, lipid gem network to possibly convey the medication securely and successfully. Nanocochleates are tube shaped (cigar-like) microstructures that comprise of a progression of lipid bilayers. Nanocochleate delivery vehicles are steady phospholipid-cation hastens made out of basic, normally happening materials, by and large phosphatidylserine and calcium. They have exceptional complex design comprising of strong, lipid bilayer sheet moved up in a winding or in stacked sheets, with practically zero inside fluid space. This construction gives insurance from corruption to related "encochleated" particles. Since the whole nanocochleate structure is a progression of strong layers and parts that are exemplified inside the inside of the nanocochleate structure which stay in one piece, despite the fact that the external layers of the nanocochleate may open to cruel ecological circumstances or proteins. Since nanocochleates contain both hydrophobic and hydrophilic surfaces, which are reasonable to embody both hydrophobic medications and hydrophilic drugs.[2]



Figure 1: Structural difference between liposomes and cochleates

COMPONENTS OF NANO-COCHLEATE DRUG DELIVERY SYSTEM [3]

The three major components used in the preparation of nanocochleates are atmospheric pressure ionization (API), lipids, and cations.

1. Lipids: Phosphatidyl serine (PS), phosphatidic acid (PA), di-oleoyl PS, phosphatidylinositol (PI), phosphatidyl glycerol (PG), phosphatidyl choline (PC), di-myristoyl PS, phosphatidyl ethanolamine (PE), di-phosphatidyl glycerol (DPG), dioleoyl phosphatidic acid, di-stearoyl phosphatidyl serine, di-palmitoyl PG.

2. Cations: Zn+2 or Ca+2 or Mg+2 or Ba+2.

Routes of administration for nanocochleate drug delivery [4]:

Nanocochleates drug delivery vehicle which permits a efficient oral delivery of medications. An elective route of administration can be arenteral, rectal, topical, sublingual, mucosal, nasal, ophthalmic, subcutaneous, intramuscular, intravenous, transdermal, spinal, intra-articular, intra-arterial, bronchial, lymphatic, and intrauterine administration, intra-vaginal or any other mucosal surfaces.

Dosage forms available for nanocochleate drug delivery:

1) For oral administration- Capsules, cachets, pills, tablet, lozenges, powders, granules, or a solution or a suspension or an emulsion.
2) For topical or transdermal administration- Powders, sprays, ointment, pastes, creams, lotions, gels, solutions, patches and inhalants.
3) For parenteral administration- Sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior use.[4]

Methods of preparation of nanocochleates:



Fig. 2. Formation of cochleates.



Fig. 3. Classification of method of preparation of nanocochleates

In the majority of the formulation methods for nanocochleates, the initial step is the preparation of liposomes. Thus nanocochleates can be classified as liposomal and non-liposomal and are displayed in Fig. 3. Liposomal techniques are arranged as as hydrogel method, trapping method, liposomes before cochleates method and binary aqueous, aqueous emulsion system, whereas the only non-liposomal method reported is direct cochleates dialysis method. [5-7]

1. Hydrogel method:

Liposomes arranged by the film hydration strategy are utilized in this procedure since it creates small unilamellar vesicles. An answer of hydrophilic polymers like dextran, polyethene glycol (Stake) is added to liposomes. The resultant dispersion is added to another immiscible polymer arrangement like polyvinyl pyrrolidone (PVP) polyvinyl liquor (PVA)/polyvinyl methyl ether. This structures the biphasic framework. Cross-connecting agent CaCl2 is then added to settle nanocochleates. This outcomes in the generation of nanocochleates. The framed nanocochleates are then saved for washing and put away in a support. When contrasted with different techniques, it gives a uniform dissemination of nanocochleates. Tobramycin nanocochleates were formed by this strategy.

2. Trapping method

Liposomes can be sorted out fundamentally by the expansion of phospholipids to water or a liquid part to phospholipid film. The dropwise expansion of CaCl2 to figured out liposomes achieves the generation of nanocochleates. By this methodology, stacked sheets or aggregates of nanocochleates are prepared. The mixture can be frustrated by expansion of assortment inhibitor like cbovine serum egg whites. Rifampicin nanocochleates were figured out by this procedure.

3. Liposomes before cochleates dialysis method

In this technique combination of lipid and cleanser are utilized as the beginning material and the expulsion of cleanser is finished by double dialysis. The blend is dialyzed at first by support and followed by calcium chloride arrangement which prompts development of cochleates. This technique is reasonable for exemplification of hydrophobic material or medication containing hydrophobic district like layer proteins.[8]

4. Binary aqueous-aqueous emulsion system

In this technique, little liposomes were framed by either high pH or by film strategy, and afterward the liposomes are blended in with a polymer, for example, a dextran. The dextran/liposome stage is then infused into a second, non-miscible, polymer (for example Stake). The calcium was then added and diffused gradually starting with one stage then onto the next framing nanocochleates. By this technique, the cochleates framed are of molecule size <1000 nm.

5. Direct calcium dialysis method

Unlike liposome before cochleate dialysis method, this technique doesn't include the transitional liposome development and the cochleates will be in size. The combination of lipid and cleanser is straightforwardly dialysed against calcium chloride arrangement. In this technique the competitionbetween the expulsion of cleanser from the cleanser/lipid/drug micelles and the buildup bi-layer by calcium, brings about thin formed huge layered structure. Combination of phosphotidylserine and cholesterol (9:1 wt proportion) in extraction cushion and non-ionic cleanser is blended in with a preselected centralization of polynucleotide and the arrangement is vortex for 5min. The unmistakable, vapid arrangement which came about is dialysed at room temperature against three changes of support. The last dialysis regularly utilized is 6mM Ca2+. The proportion of dialysed to cradle for each change is least of 1:100. The subsequent white calcium-phospholipids hastens have been named direct calcium cochleates.

Stability of nanocochleates:

As nanocochleates are produced using phospholipids which are gotten from a characteristic source, makes them less impervious to oxidation potential. The phospholipid makes tight intersection after responding with cationic salt, which brings about the arrangement of stable nanocochleates. The medication is epitomized in the strong series of the bilayer of phospholipids. After the development of nanocochleates, they are lyophilized, which makes them more steady for a delayed period and can be reconstituted by the expansion of reasonable vehicle before its utilization. This recommends the value of this clever innovation over other nanocarrier frameworks. [6–10]

Mechanism of drug release from nanocochleates:

It is expected that the nanocochleates discharge the medication when the bilayer of lipid of nanocochleates wires with the cell layer and the ideal pharmacological activity might be accomplished. (Fig. 6) One more speculation recommends the chance of phagocytosis including phosphatidylserine receptors. They are normal for lipid layer of macrophages and external film of cochleate. When cochleate moves toward nearer to the lipid film of macrophages, it wires with macrophages, bringing about the arrival of captured drug in the cytoplasm [11,12].

Advantages:

1. They are more steady than liposomes in light of the fact that the lipids in nanocochleates are less helpless to oxidation. They keep up with structure even after lyophilization, though liposome structures are annihilated by lyophilization.
2. They show effective consolidation of natural atoms, especially with hydrophobic moieties into the lipid bilayer of the cochleate structure.
3. They have the potential for slow or planned arrival of the biologic atom in vivo as nanocochleates gradually loosen up or in any case separate.
4. They have a lipid bilayer lattice which fills in as a transporter and is made out of straightforward lipids which are tracked down in creature and plant cell layers, with the goal that the lipids are non-poisonous, non-immunogenic and non-fiery.
5. They are delivered effectively and safely.[13]
6. By the utilization of nanocochleate IV Medications to be regulated orally (for example Amphotericin B, a powerful antifungal).
7. They work on oral bioavailability of an expansive range of mixtures, like those with unfortunate water dissolvability, and protein and peptide biopharmaceuticals, which have been challenging to regulate. (for example ibuprofen for arthritis).[14]

8. They lessen poisonousness stomach aggravation and opposite symptoms of the epitomized drug.
9. They exemplify or ensnare the subject medication inside a precious stone framework as opposed to synthetically holding with the medication.
10. They give insurance from debasement to the encochleated drug brought about by openness to unfavorable ecological circumstances like daylight, oxygen, water and temperature.[15]

Limitations:

1. They require explicit capacity condition.
2. Once in a while conglomeration might happen during capacity; this can be kept away from by the utilization of collection inhibitor.
3. The expense of assembling is high.

Applications

1. Improvement of a Nanocochleate based ApoA1 Definition for the Treatment of Atherosclerosis and other Coronary Heart Illnesses Hypercholesterolemia, a condition related with elevated degrees of low-density lipoproteins (LDL), and low degrees of highdensity lipoproteins (HDL), is generally acknowledged as a significant gamble factor for atherosclerosis and other cardiovascular sicknesses. The opposite connection among HDLs and heart infections is indisputably factual. HDL works with the cholesterol efflux from fringe cells and, after enzyme-mediated cholesterol esterification, transports cholesteryl esters to the body. ApoA1 (a normally existing lipoprotein) is a significant HDL accepted to be the most significant in enzymatic esterification of cholesterol and afterward its vehicle to the liver, accordingly safeguarding the vessels against artherosclerosis. Imbuement or intraperitoneal organization of ApoA1 upgrades the HDL capacity to ship cholesterol to switch and safeguard against atherosclerosis yet the significant impediment for the utilization of ApoA1 as pharmacological/restorative specialists has been the requirement for parenteral organization, as ApoA1 is a protein, it is quickly debased by GIT chemicals thus it isn't conveyed to blood as unblemished particle. So nanocochleates can give a decent stage to the conveyance of ApoA1 by oral arrangements and can get a transformation the treatment of atherosclerosis and other heart sicknesses beginning from high blood cholesterol and LDL levels.
2. Biogeode Nanocochleates can settle and safeguard a drawn out scope of micronutrients and the possibility to expand the healthy benefit of handled food sources.
3. Nanocochleates have been utilized to convey proteins, peptides and DNA for antibody and quality treatment applications.
4. Nanocochleates showed potential to convey Amphotericin B, a likely antifungal specialist, orally and parentally having a decent wellbeing profile with decreased cost of treatment. The arranged cochleates of amphotericin B showed further developed steadiness and viability at low dosages. They showed worked on understanding consistence.
5. Utilization of cochleates in the conveyance of antibacterial specialists: Cochleates would enjoy the benefit of diminishing the poisonousness and working on the bactericidal movement. For aminoglycosides and direct or cyclic peptides, cochleates ought to permit oral organization. The confirmation of standard of the adequacy of anti-TB cochleates was accomplished utilizing clofazimine as an antibacterial medication model.
6. Nanocochleates can convey Omega-3 unsaturated fats to cakes, biscuits, pasta, soups and treats without adjusting the item's taste or scent.
7. Biodelivery Sciences Global have created nanocochleates which can be utilized to convey supplements, for example, nutrients, omega unsaturated fats all the more proficiently to cells, and lycopene without influencing the variety and taste of food which makes the idea of super staples a reality, and these are supposed to offer various potential advantages including expanded energy, worked on mental capabilities, better safe capability, and antiaging benefits.

Conclusion

As nanocochleate have special multilayered structure, it safeguards dynamic specialists or mixtures which are to be conveyed. It evades contact of encochleated atom from unforgiving climate. Nanocochleates have been broadly utilized for conveyance of numerous dynamic remedial specialists by overcoming over drawbacks partners with other medication conveyance frameworks. and thus, nanocochleate drug conveyance framework is acquiring significance in drug improvement for move of appropriate and wanted drug particle into body with great potential.

References:

1. Yeole SE. A review on nanocochleate - A novel lipid based drug delivery system. J Biomed Pharm Res 2013;2:1-7.
2. Egan W.J., Lauri E.. Prediction of intestinal permeability. Adv. drug delivery review. 2002; 54:273-289.
3. Shashi K, Satinder K, Bharat P. A complete review on liposomes. International Research Journal of Pharmacy. 2012;3:10-6.
4. Florence A.T., Hussain N.. Transcytosis of nanoparticles & dendrimers delivery systems: evolving vistas. Adv. drug delivery review. 2001; 1:69-89.
5. A. Pawar, C. Bothiraja, K. Shaikh, A. Mali, An insight into cochleates, a potential drug delivery system. RSC, Advances. 5(99):81188–202 (2015 sept;).
6. R. Bhosale, P. Ghodake, A. Mane, G.A. Nanocochleates, A novel carrier for drug transfer, J. Sci. Ind. Res. 2(5):964–9 (2013 oct;).
7. V. Sankar, Y. Reddy, Nanocochleate—a new approach in lipid drug delivery, Int J Pharm Pharm Sci. 2 (4) (2010 May) 220–223.
8. Ramasamy T., Khandasamy U., Hinabindhu R., Kona K.. Nanocochleate-A New Drug Delivery System. FABAD J.Pharma.Sci. 2009; 34:91-101.
9. S. Nadaf, S. Killedar, Novel liposome derived nanoparticulate drug delivery system: Fabrication and Prospects, Cre. J. Pha. Res. sept.1(3) (2015) 117–128.

10. L. Loomba, T. Scarabelli, Metallic nanoparticles and their medicinal potential. Part II: aluminosilicates, nanobiomagnets, quantum dots and cochleates, Ther Deliv. 4 (9) (2013 Sep) 1179–1196.
11. S. Wasankar, K. Makeshwar, A. Deshmukh, B.R. Nanocochleate, A review, Research J. Pharma. Dosage Forms and Tech. 4 (3) (2012 May) 153–159.
12. S. Yeole, S. Pimple, P. Chaudhari, A review on nanocochleate–A novel lipid based drug delivery system, J Biomed Pharm Res. 2 (1) (2013 Feb) 1–7.
13. Gould-Fogerite, S., & Mannino, R. J. (1997). Cochleate delivery vehicles, U.S. Patent 5,994,318.
14. Biodelivery sciences International (2005). Retrieved September 13, 2006 from http://www.biodeliverysciences.com/AboutNanocochleateTechnology.html.
15. Biodelivery sciences International (2005). Retrieved September 13, 2006 from http://www.biodeliverysciences.com/technology/bioral.html.
16. Ö. Çoban, Z. Deg˘im, S. Yılmaz, L. Altıntas, T. Arsoy, M. Sözmen, Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma, Drug Dev. Res. 80 (5) (2019 Aug) 556–565.
17. T. Shanmugam, N. Joshi, N. Ahamad, A. Deshmukh, R. Banerjee, Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer, Int. J. Pharm. 586 (119482) (2020 May 31) 1–14.
18. T. Shanmugam, N. Joshi, A. Kaviratna, N. Ahamad, E. Bhatia, R. Banerjee, Aerosol Delivery of Paclitaxel-Containing Self-Assembled Nanocochleates for Treating Pulmonary Metastasis: An Approach Supporting Pulmonary Mechanics, ACS Biomater. Sci. Eng. 7 (1) (2021 Dec) 144–156.
19. M. Asprea, F. Tatini, V. Piazzini, F. Rossi, M. Bergonzi, B.A. Stable, monodisperse, and highly cell-permeating nanocochleates from natural soy lecithin liposomes, Pharmaceutics. 11(1):34 (2019 Jan) 1–15.
20. P. Shende, R. Khair, R. Gaud, Nanostructured cochleates: A multi-layered platform for cellular transportation of therapeutics, Drug Dev Ind Pharm. 45 (6) (2019 Jun 3) 869–881.
21. Z. Judeh, Alginate-coating of artemisinin-loaded cochleates results in better control over gastro-intestinal release for effective oral delivery, Journal of Drug Delivery Science and Technology. 1 (52) (2019 Aug) 27–36.
22. Machín L, Tamargo B, Piñón A, Atíes R, Scull R, Setzer W, Monzote L. Bixa orellana L.(Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) Essential oils formulated in nanocochleates against leishmania amazonensis. Molecules. 2019 Jan;24(23):4222:1-10.
23. D. Delmarre, R. Lu, N. Tatton, S. Krause-Elsmore, S. Gould-Fogerite, R. Mannino, Formulation of hydrophobic drugs into cochleate delivery vehicles: A simplified protocol & formulation kit, Drug delivery technology. 4 (1) (2004) 64–69.
24. Bhosale RR, Ghodake PP, Nandkumar A, Mane AG. Nanocochleates: A novel carrier fordrug transfer. J Sci Innov Res 2013;2:964-9.
25. Syed UM, Woo AF, Plakogiannis F, Jin T, Zhu H. Cochleates bridged by drug molecules. Int J Pharm 2008;363:118-25.
26. Zarif L, Graybill JR, Perlin D, Najvar L, Bocanegra R, Mannino RJ. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model. Antimicrob Agents Chemother 2000;44:1463-9.
27. Sampaio JL, Moreno MJ, Vaz WL. Kinetics and thermodynamics of association of a fluorescent lysophospholipid derivative with lipid bilayers in liquid-ordered and liquid-disordered phases. Biophys J 2005;88:4064-71.
28. Villa AM, Caporizzo E, Papagni A, Miozzo L, Del Buttero P, Grilli MD, *et al.* Choline and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by laser scanning confocal fluorescence microscopy. Eur J Cancer 2005;41:1453-9.
29. Landge A, Pawar A, Shaikh K. Investigation of cochleates as carriers for topical drug delivery. Int J Pharm Pharm Sci 2013;5:314-25.
30. Zarif L, Perlin D. Amphotericin B nanocochleates: From formulation to oral efficacy drug. Deliv Technol 2002;2:34-7.
31. Zarif L. Elongated supramolecular assemblies in drug delivery. J Control Release 2002;81:7-23.
32. Zarif L, Jin T, Segarra I, Mannino RJ. Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules. Google Patents; 2003.
33. Jagdale G, Warad S. Nanocochleates: A novel approach. World J Pharm Pharm Sci 2013;2:2539-59.
34. Yeole SE, Pimple SS, Chaudhari PD. A review on nanocochleate – A novel lipid based drug delivery system. J Biomed Pharm Res 2013;2:1-7.
35. Gould-Fogerite S, Mannino RJ. Cochleate delivery vehicles, U.S. Patent 5,994, 318; 1997.